glp-1 and ulcerative colitis The Potential for GLP-1s in the Treatment of GLP-1 Drugs: For Multiple Chronic

In a large Phase 3 clinical trial published in the New England Journal of Medicine, people who took the highest dose of the Wegovy pill lost an average of 16.6 percent of their body weight after 64 weeks

In addition, our data unambiguously documented that the effects of this and other multi-functional analogs on body weight and food intake are not merely due to food aversion or malaise linked to gastrointestinal distress, regarded as one of the main side-effects of GLP1-based therapy in humans 49

New England Journal of Medicine, 375 ,

"Research shows that it is possible to improve many complications of obesity like diabetes, high blood pressure and cholesterol, heart and kidney failure, sleep apnea, excessive liver fat, and even osteoarthritis with these medications," says Dr